Can-Fite BioPharma (CANF)
XASE:CANF
CANF Stock Chart & Stats
$4.04
-$0.06(-3.61%)
At close: 4:00 PM EST
$4.04
-$0.06(-3.61%)
Day’s Range― - ―
52-Week Range$2.90 - $36.40
Previous CloseN/A
Volume35.97K
Average Volume (3M)258.05K
Market Cap
$6.84M
Enterprise Value$8.34B
Total Cash (Recent Filing)$6.46M
Total Debt (Recent Filing)$90.00K
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding2,142,546
10 Day Avg. Volume432,468
30 Day Avg. Volume258,053
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)8.07
P/FCF Ratio-0.37
Enterprise Value/Market Cap1.22K
Enterprise Value/Revenue14.89K
Enterprise Value/Gross Profit14.89K
Enterprise Value/Ebitda-936.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.72
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened Global IP For Namodenoson (anti‑obesity)A multi‑jurisdiction patent estate around Namodenoson’s anti‑obesity use creates a durable barrier to direct copycat entrants, improves bargaining leverage for licensing or partnerships, and underpins longer‑term commercialization options across major markets if clinical efficacy is proven.
Broad Clinical Pipeline With Favorable Safety SignalsConsistent favorable safety across oncology and liver programs reduces regulatory and development risk, enabling longer trials, combination studies, and potential accelerated pathways. Safety credibility strengthens partnerability and supports multiple indication development strategies over the medium term.
Low Leverage / Conservative Balance SheetMinimal debt lowers insolvency and interest burden risks, preserving operational flexibility during multi‑year clinical programs. Low leverage provides durable capacity to raise funds without immediate balance‑sheet distress, giving management time to advance trials or negotiate partnerships.
Bears Say
Consistent Negative Operating And Free Cash FlowOngoing negative cash flow is a structural constraint: it necessitates recurring external financing, can force program prioritization or delays, and raises dilution risk. Persistent burn limits the firm’s ability to scale development activities without predictable, long‑term funding sources.
Declining Revenue And Persistent Operating LossesShrinking revenues and sustained losses reduce internal funding capacity and signal limited current commercial traction. This weak financial trajectory constrains strategic options, increases dependence on partners or financings, and makes long‑term self‑sustainability contingent on clinical success.
Clinical‑stage Company With No Commercial ProductsBeing pre‑commercial means value is binary and tied to trial outcomes and approvals. Long development timelines, regulatory uncertainty, and the need for successful pivotal data create structural execution risk; until approvals, revenue generation and profitability remain uncertain.
Can-Fite BioPharma News
CANF FAQ
What was Can-Fite BioPharma’s price range in the past 12 months?
Can-Fite BioPharma lowest stock price was $2.90 and its highest was $36.40 in the past 12 months.
What is Can-Fite BioPharma’s market cap?
Can-Fite BioPharma’s market cap is $6.84M.
When is Can-Fite BioPharma’s upcoming earnings report date?
Can-Fite BioPharma’s upcoming earnings report date is Aug 27, 2026 which is in 136 days.
How were Can-Fite BioPharma’s earnings last quarter?
Can-Fite BioPharma released its earnings results on Mar 26, 2026. The company reported -$0.126 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.014.
Is Can-Fite BioPharma overvalued?
According to Wall Street analysts Can-Fite BioPharma’s price is currently Overvalued.
Does Can-Fite BioPharma pay dividends?
Can-Fite BioPharma does not currently pay dividends.
What is Can-Fite BioPharma’s EPS estimate?
Can-Fite BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Can-Fite BioPharma have?
Can-Fite BioPharma has 2,142,546 shares outstanding.
What happened to Can-Fite BioPharma’s price movement after its last earnings report?
Can-Fite BioPharma reported an EPS of -$0.126 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went up 1.858%.
Which hedge fund is a major shareholder of Can-Fite BioPharma?
Currently, no hedge funds are holding shares in CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.